Volume 15 Supplement 3

Gastroprotective NSAIDS

Reviews

Edited by Lee Simon (Guest Editor)

The supplement was proposed by the journal and developed by the journal in collaboration with the Guest Editor. The Guest Editor assisted the journal in preparing the outline for the project but did not have oversight of the peer review process. The Guest Editor serves as a clinical and regulatory consultant in drug development and has served as such consultant for companies which manufacture and market NSAIDS including Pfizer, Pozen, Horizon Pharma, Logical Therapeutics, Nuvo Research, Iroko Imprimis, JRX Pharma, Nuvon, Medarx, Asahi. The articles have been through the journal's standard peer review process. Publication of this supplement has been supported by Horizon Pharma Inc. Duexis (ibuprofen and famotidine) is a product marketed by the sponsor.

Nonsteroidal anti-inflammatory drugs and their risk: a story still in development

Authors: Lee S Simon

Citation: Arthritis Research & Therapy 2013 15(Suppl 3):S1

Content type: Introduction Published on: 24 July 2013
- View Full Text
- View PDF
Use of NSAIDs in treating patients with arthritis

Patients with rheumatic diseases, including rheumatoid arthritis and osteoarthritis, almost universally describe pain and stiffness as important contributors to reduced health-related quality of life. Of the t...

Authors: Leslie J Crofford

Citation: Arthritis Research & Therapy 2013 15(Suppl 3):S2

Content type: Review Published on: 24 July 2013
- View Full Text
- View PDF
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage

NSAIDs are among the most commonly used drugs worldwide and their beneficial therapeutic properties are thoroughly accepted. However, they are also associated with gastrointestinal (GI) adverse events. NSAIDs ...

Authors: Carlos Sostres, Carla J Gargallo and Angel Lanas

Citation: Arthritis Research & Therapy 2013 15(Suppl 3):S3

Content type: Review Published on: 24 July 2013
- View Full Text
- View PDF
Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage

The characteristic of a biomarker that makes it a useful surrogate is the ability to identify a high risk of clinically important benefits or harms occurring in the future. A number of definitions or descripti...

Authors: R Andrew Moore

Citation: Arthritis Research & Therapy 2013 15(Suppl 3):S4

Content type: Review Published on: 24 July 2013
- View Full Text
- View PDF
The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage

NSAIDs are prescribed widely but have rare serious gastrointestinal side effects. More recently, adverse cardiovascular effects of these drugs have also been recognized, leading to the withdrawal of some agent...

Authors: James M Scheiman

Citation: Arthritis Research & Therapy 2013 15(Suppl 3):S5

Content type: Review Published on: 24 July 2013
- View Full Text
- View PDF
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage

Pain affects the quality of life for millions of individuals and is a major reason for healthcare utilization. As populations age, medical personnel will need to manage more and more patients suffering from pa...

Authors: Anne Tuskey and David Peura

Citation: Arthritis Research & Therapy 2013 15(Suppl 3):S6

Content type: Review Published on: 24 July 2013
- View Full Text
- View PDF

Gastroprotective NSAIDS

Reviews

Nonsteroidal anti-inflammatory drugs and their risk: a story still in development

Use of NSAIDs in treating patients with arthritis

Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage

Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage

The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage

The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage

Follow

Annual Journal Metrics

Arthritis Research & Therapy

Contact us